MedTrace Logo

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2026-08-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Conditions

Interventions

DRUG

Elecoglipron

Elecoglipron is administered orally once daily.

DRUG

Dapagliflozin

Dapagliflozin administered orally once daily.

DRUG

Elecoglipron-matched placebo

A placebo matching elecoglipron administered orally once daily.

DRUG

Dapagliflozin-matched placebo

A placebo matching dapagliflozin administered orally once daily.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-06
Primary Completion
2028-07-05
Completion
2028-07-05
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • China
  • Czechia
  • Denmark
  • Germany
  • Greece
  • Hungary
  • India
  • Japan
  • Malaysia
  • Mexico
  • Poland
  • Puerto Rico
  • Slovakia
  • South Africa
  • South Korea
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07662109 on ClinicalTrials.gov